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Abstract
Nuclear medicine imaging is a powerful diagnostic tool for the management of patients with gastro-entero-pancreatic
neuroendocrine tumors, mainly developed considering some cellular characteristics that are specific to the neuroen-
docrine phenotype. Hence, overexpression of specific trans membrane receptors as well as the cellular ability to take
up, accumulate, and decarboxylate amine precursors have been considered for diagnostic radiotracer development.
Moreover, the glycolytic metabolism, which is not a specific energetic pathway of neuroendocrine tumors, has been
proposed for radionuclide imaging of neuroendocrine tumors. The results of scintigraphic examinations reflect the
pathologic features and tumor metabolic properties, allowing the in vivo characterization of the disease. In this article,
the influence of both cellular differentiation and tumor grade in the scintigraphic pattern is reviewed according to the
literature data. The relationship between nuclear imaging results and prognosis is also discussed. Despite the existence
of a relationship between the results of scintigraphic imaging and cellular differentiation, tumor grade and patient
outcome, the mechanism explaining the variability of the results needs further investigation.
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Introduction and rationale
Neuroendocrine tumors (NET) are epithelial neoplasms
with neuroendocrine differentiation. NETs are a hetero-
geneous group of rare tumors originating from peptide-
and amine-producing cells of the neuroendocrine system.
Their incidence is usually reported at between 40 and
50 cases per million, accounting for approximately
0.5% of all malignant neoplasms. Although most NETs
originate from the gastrointestinal tract and pancreas,
they only make up 2% of all gastro-entero-pancreatic
(GEP) malignancies[1].
Only a small proportion of a GEPNET is functional.
Flushes and diarrhea are the most reported symptoms
related to the tumoral secretion of biologically active
peptides and amines[2]. The clinical symptomatology of
GEPNET is generally associated with the presence of
systemic metastatic spread. However, bowel obstruction
or incidental detection of hepatic metastases are common
circumstances that lead to diagnosis. Extensive tumor
bulk and metastatic disease are the major causes of
death. However, long patient survival, which is mainly
related to the slow-growing tumor characteristics, is not
unusual[3].
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Nowadays, surgery of the primary tumor is the only
curative treatment in patients without metastatic dis-
ease[4]. Unfortunately, the detection of liver metastases
at primary staging generally limits the possibility of com-
plete surgical eradication. Hence, accurate staging is cru-
cial to define the real extent of the disease and to identify
patients with inoperable tumors[5,6].
Evidence exists that tumor differentiation and grade
are related to the clinical behavior of GEPNETs[7,8].
Differentiation refers to the extent to which the tumor
cells resemble their non-neoplastic counterparts. Well-dif-
ferentiated GEPNETs present a low mitotic activity, and
may have punctate necrosis. Cells are uniform and pro-
duce neurosecretory granules. Poorly differentiated neu-
roendocrine carcinomas show fields of necrosis, less
cytoplasmic granularity, irregular nuclei, and marked cel-
lular pleomorphism. The distinction between a well-differ-
entiated and a poorly differentiated NET is one of the
most important pathologic assessments: the first are
rather indolent, whereas the second are likely to be
more aggressive. Grade refers to the degree of biological
aggressiveness of the tumor, without taking into account
the pathologic differentiation. Low-grade NETs are gen-
erally considered as the least aggressive in behavior.
On the other hand, high-grade tumors tend to grow rap-
idly and spread faster than tumors with lower grade.
Intermediate grade NETs have a less predictable and
moderately aggressive course. The proliferative rate can
be assessed as the number of mitoses per unit area of
tumor or as the percentage of neoplastic cells immuno-
labeling for the proliferation marker Ki-67. The Ki-67
index is related to the presence of the Ki-67 protein in
the active phases of the cell cycle. Ki-67 is a proliferation
marker commonly used in all grading systems and it is
currently reported in pathology reports[9]. A Ki-67 index
less than 2%, between 3% and 20%, and above 20%, is
characteristic of low, intermediate, and high-grade
GEPNET, respectively. Well-differentiated GEPNETs
are classified as either low or intermediate grade, whereas
poorly differentiated GEPNETs are classified as high
grade in all cases[7,10]. The existence of a high-grade
well-differentiated tumor is controversial, and does not
figure in any expert recommendation or guideline[11].
Medical imaging is crucial for the management of NET
patients. A multidisciplinary morphofunctional approach
has been advocated, associating radiologic and nuclear
medicine examinations. Nuclear medicine imaging
for NET has been mainly developed considering
some cellular characteristics that are specific for the neu-
roendocrine phenotype. Hence, the overexpression of
specific trans membrane receptors as well as the
cellular ability to take up, accumulate, and decarboxylate
amine precursors have been considered for diagnostic
radiotracer development[12]. Moreover, the glycolytic
metabolism, which is not a specific energetic pathway
of NETs, has been proposed for NET radionuclide
imaging.
In this article, we briefly review the nuclear medicine
diagnostic procedures that are mainly used in clinical
practice for NET imaging. The influence of both cellular
differentiation and tumor grade in the choice of isotopic
examination is examined. The possible relationship
between the result of nuclear imaging and patient prog-
nosis is discussed. The main bibliographic data about
GEPNETs reported in the article are summarized in
Table 1.
Table 1 Main bibliographic data on GEPNET reporting: functional imaging, tumor grade, tumor differentiation or
patient outcome results
Author Reference Patients Patients
with
GEPNET
SRS Somatostatin
imaging with
PET analogs
FDOPA
PET
FDG
PET
Tumor
grade
Cellular
differentiation
Patient
outcome
Gabriel et al. [22] 84 50 þ þ
Buchmann et al. [23] 27 15 þ þ
Srirajaskanthan et al. [24] 51 37 þ þ þ
Koopmans et al. [33] 53 32 þ þ
Montravers et al. [34] 30 23 þ þ
Ambrosini et al. [44] 13 11 þ þ
Ambrosini et al. [35] 13 13 þ þ
Haug et al. [45] 25 14 þ þ
Campana et al. [49] 47 41 þ þ þ þ
Adams et al. [50] 15 7 þ þ þ þ
Belhocine et al. [51] 17 11 þ þ þ þ
Kayani et al. [52] 38 28 þ þ þ þ
Binderup et al. [29] 96 81 þ þ þ
Abgral et al. [54] 18 15 þ þ þ þ þ
Garin et al. [56] 31 23 þ þ þ þ þ
Binderup et al. [57] 98 83 þ þ þ
Asnacios et al. [58] 98 53 þ þ
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Nuclear medicine imaging:
a brief overview
Somatostatin receptor-based imaging
Somatostatin is a peptide produced by both paracrine
and endocrine cells in the GEP tract. Somatostatin recep-
tors (sstr) are coupled to cell membrane G-proteins.
Five sstr subtypes are known, designated sstr1 to 5.
In NETs, sstr2 and sstr5 are particularly abundant[13].
Overexpression of receptors as well as internalization of
the hormonereceptor complex are the basis of radiola-
beled somatostatin imaging modalities. Octreotide conju-
gated with diethylene-triamine-pentaacetic acid (DTPA)
and labeled with 111In is a radiolabeled somatostatin
analog with great affinity for sstr2 and widely used in
clinical practice[14,15].
Somatostatin receptor scintigraphy (SRS) is routinely
indicated for staging purposes and during follow-up in
patients with GEPNETs. Good sensitivity and specificity
have been reported for SRS, irrespective of tumor site
and hormonal secretion[16]. SRS sensitivity is mainly
related to the tumoral sstr2 density, decreasing for
poorly differentiated tumors[13,16]. The introduction of
multiple-head gamma cameras and tomographic acquisi-
tion by single photon emission computed tomography
(SPECT) has provided three-dimensional imaging,
improving sensitivity[17]. Moreover, the latest generation
of high-resolution gamma cameras coupled with
multidetector computed tomography (SPECT/CT)
allows accurate anatomic localization of functional
abnormalities[18,19], as well as a reduction in study dura-
tion and patient discomfort. Nevertheless, SRS is limited
by the unfavorable physical characteristics of 111In, redu-
cing the detection of small lesions, especially in organs
with physiologic tracer uptake such as the liver.
Accordingly, an inverse relationship between SRS sensi-
tivity and the size of hepatic metastasis has been pre-
viously reported[20]. EDDA/HYNIC-Tyr3-octreotide is a
99mTc-radiolabeled peptide that has been developed in
Poland for clinical investigations and intraoperative
detection of NETs. According to the results reported
by Hubalewska-Dydejczyk et al.[21], the high-quality
99mTc-EDDA/HYNIC-octreotate images revealed more
metastases than 111In-octreotide SRS with better individ-
ual lesion separation and seemed more accurate in iden-
tifying the site of unknown primary tumors in patients
with metastatic NETs.
Both the relatively low spatial resolution of common
gamma cameras and the prolonged acquisition time
of SRS have led to the development of new soma-
tostatin analogs labeled with 68Ga for positron emission
tomography (PET) studies, such as [68Ga-DOTA0-
Tyr3]octreotide (68Ga-DOTA-TOC), [68Ga-DOTA0-
Tyr3]octreotate (68Ga-DOTA-TATE) and [68Ga-
DOTA0-1NaI3]octreotide (68Ga-DOTA-NOC). PET has
an increased sensitivity towards SPECT, explained by a
two- to threefold higher spatial resolution and a better
tumor-to-background ratio. Higher sensitivity than SRS
has been reported in most published clinical investiga-
tions[22,23], in particular for the detection of small
lymph node metastases and secondary bone localizations,
providing modification of therapeutic strategy[24]. 64Cu-
labeled octreotide conjugates have also been evaluated.
In particular, 64Cu-TETA-D-Phe1-octreotide binds to the
somatostatin receptor with 5 times the affinity of 111In-
octreotide, representing a potential agent for PET ima-
ging of NETs[25]. Unfortunately, the availability of the
somatostatin PET analogs is still scarce, whereas SRS is
routinely performed in almost all nuclear medicine
facilities.
Somatostatin receptor-based functional imaging by
SPECT and PET contributed to the development of alter-
native therapeutic strategies such as radiometabolic ther-
apy with b-emitter labeled somatostatin analogs. One of
the most relevant applications of SSR imaging is proba-
bly to select patients with well-differentiated and inoper-
able NETs who are potentially candidates for peptide
receptor radionuclide therapy with 90Y and/or 177Lu radi-
olabeled somatostatin analogs[26,27].
Catecholamine pathway-based imaging
GEPNETs originate from the amine precursor uptake
and decarboxylation (APUD) system[12]. Accordingly,
the re-uptake of norepinephrine and the uptake of
amine substrates such as dihydroxyphenylalanine
(DOPA) have been exploited for nuclear medicine radio-
tracer development.
123I or 131I radiolabeled meta-iodobenzylguanidine
(mIBG) is a structural analog of norepinephrine used
for clinical imaging. mIBG uses active transport mechan-
isms to accumulate in the tumor in secretory vesicles. The
sensitivity of mIBG scintigraphy for GEPNET has been
reported to be about 50%, which is lower than the sensi-
tivity of SRS[28,29]. Although 123I-mIBG is less sensitive
for GEPNET detection, it remains useful to predict
uptake and response to radionuclide therapy with 131I-
labeled mIBG. 123I-mIBG scans remain the first choice in
nuclear medicine imaging for the management of patients
with pheochromocytoma and neuroblastoma[30].
DOPA is an intermediate product in the synthesis of
dopamine. Cellular uptake of DOPA is related to a spe-
cific cell membrane transport system. Once internalized,
DOPA is decarboxylated to dopamine, and transported
into secretory vesicles[31]. For nuclear imaging purposes,
DOPA is labeled with 18F (FDOPA) leading to the accu-
mulation of 18F-dopamine in the cell. The high uptake of
FDOPA in NETs is the result of the increased synthesis,
storage and secretion of biogenic amines[32]. FDOPA
PET seems to be superior to morphological imaging
and SRS in the localization of both the primary site
of the GEPNET and metastatic localizations[33,34].
Moreover, some authors have suggested that FDOPA
PET is a valuable imaging tool for the detection of the
primary tumor in patients with metastatic GEPNET of
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unknown origin and negative or inconclusive findings at
conventional imaging and SRS[35] (Fig. 1). However, its
high cost and low availability are still important limiting
factors for the routine use of FDOPA in clinical practice.
11C-5-Hydroxytryptophan (HTP) is a radiolabeled ser-
otonin precursor representing an FDOPA-alternative
related radiotracer. HTP is specifically taken up by carci-
noid serotonin-producing tumors, decarboxylated by aro-
matic amino acid decarboxylase (AADC), and stored in
vesicles as 11C-serotonin and was shown to be more sen-
sitive in imaging small NET lesions[3638]. Uptake, dec-
arboxylation, and secretory vesicle transportation rely on
the same systems and enzyme as FDOPA. However, the
short half-life of 11C requires an on-site cyclotron facility,
making HTP not widely available for routine clinical use.
The sensitivity of FDOPA and HTP PET may be
reduced for the detection of well-differentiated pancreatic
NET due to high physiologic radiotracer uptake and
retention in the whole pancreas. As recently reported
by Tessonnier et al.[39] in 4 patients with solitary insuli-
nomas, FDOPA PET identified tumor in only one case.
The administration of carbidopa, an efficient inhibitor of
the peripheral aromatic amino acid decarboxylase
(AADC), has been shown to improve image interpreta-
tion for FDOPA and HTP PET by increasing tumoral
uptake and lowering physiologic pancreatic
uptake[32,40]. On the other hand, no final consensus
has been reached about the usefulness of AADC inhibi-
tion by carbidopa premedication before an FDOPA
PET study in patients with insulinomas or b-cell
hyperplasia[4143].
Nowadays, few comparative studies investigating the
diagnostic role of FDOPA and 68Ga-DOTA-NOC or
68Ga-DOTA-TATE PET/CT in GEPNET are available.
Ambrosini et al.[44] reported a higher accuracy of 68Ga-
DOTA-NOC in the detection of primary tumor and meta-
static disease compared with FDOPA in 11 patients with
GEPNET. The detection rate of primary tumor with
FDOPA was lower than previously reported by the
same authors[35]. These results are confirmed by Haug
et al.[45], who reported a clear superiority of 68Ga-DOTA-
TATE to FDOPA PET in 14 patients. Nevertheless, pro-
spective studies including larger and more homogeneous
patient series are necessary to confirm the real superiority
of PET/CT with somatostatin analogs towards FDOPA
PET/CT in the diagnosis and follow-up of patients with
GEPNET.
Glucose metabolism-based imaging
18F-Fluoro-2-deoxy-D-glucose (FDG) is a glucose analog
labeled with positron-emitting 18F, which is taken up into
cells by the glucose molecular transporter. Once interna-
lized, FDG is phosphorylated without entering any
Figure 1 Results of FDOPA PET (A,C) and SRS (B,E) performed in a 56-year-old patient presenting hepatic metas-
tases (D) of a well-differentiated NET of unknown origin (Ki-67, 5%). SRS allowed the visualization of multiple foci
of pathologic uptake in the liver, lymph nodes and bones without evidence of the primary tumor. FDOPA PET confirmed
massive bone marrow and skeletal involvement, as well as multiple lymphatic and hepatic metastases. Moreover,
FDOPA PET demonstrated intense and focal uptake in the head of pancreas (arrowhead), later confirmed as the
primary tumor.
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further metabolic processes. Thus, FDG remains trapped
within the cell. The widespread clinical use in oncological
routine of FDG PET as an imaging tool capable of
exploring the differences of glucose metabolic activity
between normal and pathologic tissues is justified by its
high diagnostic accuracy and therapeutic impact.
Nevertheless, limited value of FDG PET/CT is usually
reported in the management of NETs, probably because
of their low metabolic activity and slow growth. Despite
these premises, FDG PET could have a potential value
for prognosis stratification in patients with NET, as sug-
gested by Strauss et al.[46] in the early 1990s.
Accordingly, NET with increased FDG uptake seem to
have a more aggressive behavior with consequent less
favorable long-term prognosis[47].
Functional characterization of GEPNET
by nuclear medicine imaging
Imaging results according to differentiation
and tumor grade
The expression of sstr on the cell surface is a landmark of
neuroendocrine differentiation. Well-differentiated NETs
are characterized by an important sstr density explaining
the good sensitivity of nuclear imaging based on radiola-
beled somatostatin analogs[13]. On the other hand, less-
differentiated tumors lose their ability to express sstr[48]
with consequent reduction in the diagnostic interest of
SRS. Campana et al.[49] reported a significant correlation
between the scintigraphic results and NET differentiation
in 47 patients studied by 68Ga-DOTA-NOC PET/CT.
They showed that the intensity of radiotracer uptake
was higher in well-differentiated tumors. They also
demonstrated the relationship between the degree of
radiotracer uptake and the clinical and pathologic fea-
tures of NET. In the same manner, Srirajaskanthan
et al.[24] found a decreased sensitivity of 68Ga-DOTA-
TATE PET/CT in patients with poorly differentiated
NET.
An inverse relationship between FDG uptake and
tumor differentiation has been observed. Increased glyco-
lytic metabolism has been associated with high prolifera-
tive and poorly differentiated NETs[50]. Conversely, a
higher rate of false-negative results of FDG PET was
found comparing FDG PET and SRS in patients with
well-differentiated GEPNET[51].
Based on these observations, the mismatch high uptake
of somatostatin analogs/low glycolytic metabolism could
be considered as the scintigraphic pattern of well-differ-
entiated GEPNETs. Conversely, the scintigraphic pattern
low uptake of somatostatin analogs/high glycolytic
metabolism could be considered as representative of
poorly differentiated tumors.
The potential relationship between the tumor grade
and the results of scintigraphic exploration by labeled
somatostatin analogs and FDG has still not been
completely elucidated. For this purpose, Kayani
et al.[52] compared the diagnostic performances of
68Ga-DOTA-TATE and FDG PET/CT in 28 patients
with GEPNET and 4 patients with metastatic NET of
unknown origin. In this patient cohort, the uptake of
68Ga-DOTA-TATE was globally higher in low-grade
NETs (Ki-67 less than 2%) than high-grade tumors.
Conversely, lesions with a Ki-67 index above 20%
showed a significantly higher FDG uptake. In patients
with low-grade NET, only 21 of 123 detected lesions
were FDG avid; 120 lesions showed 18Ga-DOTA-TATE
uptake. In high-grade NETs, only 5 of 79 detected lesions
were positive with 68Ga-DOTA-TATE, whereas 77 were
positive for 18F-FDG uptake. Moreover, no lesion exhib-
ited exclusive uptake of either 68Ga-DOTA-TATE in high-
grade or FDG in low-grade NETs. In this study, tumor
grade was even predictive of scintigraphic pattern.
Binderup et al.[29] prospectively performed SRS and
FDG PET/CT on 96 consecutive patients with NET
including 81 cases of GEPNET. The sensitivity of both
techniques was analyzed according to the proliferative
index. The authors reported a higher sensitivity of FDG
PET in tumors with a proliferative index above 2%. FDG
sensitivity was even better when the proliferative rate was
above 15%. Conversely, SRS sensitivity was found to be
significantly higher for tumors with a proliferation index
below 15%. To our knowledge, no published data asses-
sing a potential relationship between FDOPA uptake and
either pathologic differentiation or tumor grade are avail-
able yet (Figs. 2, 3 and 4).
According to these results, it seems possible to predict
in vivo and with good accuracy both tumor grade and
cellular differentiation from the analysis of nuclear med-
icine examinations. Moreover, the 2 scintigraphic pat-
terns previously reported for tumor differentiation
(i.e. high uptake of somatostatin analogs/low glycolytic
metabolism versus low uptake of somatostatin analogs/
high glycolytic metabolism) could also be appropriate for
the grade[53].
Although well-differentiated NETs are often low-grade
lesions, the finding of a well-differentiated endocrine car-
cinoma with a high Ki-67 index is of importance, increas-
ing the interest for proliferative index estimation as a
powerful prognostic tool. Currently, the choice of scinti-
graphic examination is mainly guided by tumor differen-
tiation. Nevertheless, evidence exists about the important
role played by tumor aggressiveness independently of the
degree of cellular differentiation. For this purpose,
Abgral et al.[54] recently investigated the performances
of SRS and FDG PET/CT in a rare subgroup of 18
patients with stage IV well-differentiated endocrine carci-
noma characterized by a Ki-67 index above or equal to
10%. On a per patient analysis, SRS and FDG PET sen-
sitivity was 83% and 100%, respectively. Taking as a stan-
dard the highest number of distinct lesions visualized by
at least one imaging method (per lesion analysis), the
sensitivities of SRS and FDG PET were 43% and 77%,
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respectively, with a statistically significant superiority of
FDG PET for detection of lymph node involvement.
According to these results, the authors proposed FDG
PET as the first choice scintigraphic method for staging
of metastatic well-differentiated endocrine carcinoma
with Ki-67 of 10% or higher.
All this evidence suggests that an intimate relationship
between tumor differentiation and grade could explain
the variability in the results of nuclear medicine examina-
tions. Nevertheless, the exact influence of one on the
another has still not been completely elucidated.
Nuclear imaging results for patient
outcome prediction
There is a growing body of evidence suggesting the poten-
tiality of FDG PET/CT in the prediction of long-term
prognosis in patients with NET. A correlation between
the intensity of tumoral radiotracer uptake and survival
has been reported. Pasquali et al.[55] first reported the
accuracy of FDG PET for identifying NETs with rapidly
growing or aggressive behavior, supporting the evidence
that an increased glycolytic rate reveals a worse progno-
sis. More recently, Garin et al.[56] evaluated the prognos-
tic value of FDG PET/CT in a prospective study
enrolling 38 patients with metastatic well-differentiated
NET. The pancreas or small intestine was the site of
the primary tumor in 20 of 38 patients. Histologically,
4 patients had a high-grade tumor and 34 had a low-grade
tumor. Overall positive and negative predictive value of
FDG PET/CT for the detection of disease progression
within the first 6 months of follow-up was 93% and 91%,
respectively. FDG PET/CT was found to be more sensi-
tive than pathologic differentiation and Ki-67 in the early
prediction of rapidly progressive disease. In 4 cases, there
was a discrepancy between the pathologic examination
(showing a well-differentiated tumor) and the Ki-67
immunostaining diagnosing a high-grade phenotype.
These results are consistent with the recent work of
Binderup et al.[57] based on a population of 98 patients
with NET including 83 GEPNETs, 8 bronchopulmonary
carcinoid tumors and 7 primary tumors of unknown
origin. In this study, the prognostic value of FDG
uptake, the proliferation index, chromogranin A, and
liver metastases were assessed. During the 1-year
follow-up, 13 of 14 dead patients were FDG PET positive
and only one was FDG PET negative. Five of 13 lethal
tumors showed a proliferation index below 2%, among
which 4 showed FDG uptake. In this study, the positive
prognostic value of FDG PET for the prediction of
patient outcome was better than the Ki-67 index.
Conversely, positive findings with NET-specific radio-
tracers seem to be associated with a less aggressive dis-
ease and a better patient outcome. Asnacios et al.[58]
recently evaluated the correlation between SRS, sstr
expression, and prognosis. Consecutive patients with
Figure 2 FDG (A,C) and FDOPA PET/CT (B,E) results performed before liver transplantation in a 49-year-old patient
with a history of well-differentiated ileal NET surgically treated (Ki-67, 1%). Intense uptake of FDOPA was observed in
multiple and voluminous hepatic metastases. FDG PET showed no or minimal uptake in the liver lesions.
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a well-differentiated NET and negative (48 patients) or
positive (50 patients) findings at SRS, were compared.
The authors reported a better overall survival at 60
months when SRS was positive. Even in the absence of
any treatment, SRS proved to be a valuable prognostic
tool. Similar results were shown by Campana et al.[49]
investigating 47 patients with NET by 68Ga-DOTA-NOC
PET/CT.
Figure 3 Results of FDG PET (A,C), SRS-SPECT (B,E) and corresponding non-enhanced CT slice (D) performed in a
63-year-old patient with poorly differentiated rectal NET (Ki-67, 11%). FDG PET allowed the detection of the primary
tumor and both lymphatic para-aortic and right-lobe hepatic metastases. On the other hand, SRS showed no pathologic
uptake, particularly in the liver (arrowheads).
Figure 4 SRS (A), FDOPA (B,D) and FDG PET/CT (C,F) results performed for restaging purposes in a 66-year-old
patient with a history of well-differentiated colic NET (Ki-67, 2%) previously treated by surgery. SRS only showed faint
uptake concerning a peritoneal relapse (*). FDOPA PET showed a clear multifocal peritoneal carcinomatosis (arrow-
head) and multiple hepatic metastases. Despite the absence of focal FDG uptake, diffuse and moderate uptake was
observed in the pelvic cavity suggesting the shield sign, in keeping with peritoneal carcinomatosis.
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Summary and conclusion
Nuclear medicine is a valuable non-invasive diagnostic
modality for the staging and follow-up of patients with
GEPNET. The results of scintigraphic examinations
reflect the pathologic features and metabolic properties
of the tumors, making the in vivo characterization of
tumor differentiation and grade possible. The 2 scinti-
graphic patterns previously described (i.e. high uptake
of somatostatin analogs/low glycolytic metabolism
versus low uptake of somatostatin analogs/high glycolytic
metabolism) could be considered as the extremes of all
possible results. However, this binary-like classification is
not applicable in all situations. A continuum of results
combining a variable uptake degree of specific (radiola-
beled somatostatin analogs, FDOPA) and non-specific
(FDG) radiotracers is usually encountered in daily prac-
tice. The uptake intensity of radiolabeled analogs of
somatostatin, FDOPA and FDG can vary in different
lesions in the same patient mainly reflecting the tumor
heterogeneity but also a possible variable degree of tumor
differentiation (Fig. 5).
Even if cellular differentiation is commonly related to
tumor grade, some exceptions exist, making both assess-
ments necessary[54,57]. The association of multitracer
nuclear investigations could play a role in the assessment
of tumor differentiation and grade in a non-invasive
manner, increasing the diagnostic accuracy and orienting
therapeutic strategies[29,52,54,56]. In particular, the assess-
ment of glycolytic metabolism by FDG PET seems to
be potentially useful in identifying high-risk patients
with more aggressive tumors, especially in those
cases where there is disagreement between the
pathologic results obtained from the biopsy of a meta-
static location and the primary tumor after surgical
debulking (Fig. 6).
Figure 5 Multiple hepatic metastases (C,D, contrast-enhanced CT maximum projection intensity and axial slice
performed some days after the scintigraphic examinations) in a 57-year-old patient with poorly differentiated pancreatic
NET previously treated by surgery. Biopsy confirmed the neuroendocrine nature of one hepatic lesion. The pathologic
report showed a well-differentiated NET (Ki-67,53%). Several hepatic foci of pathologic uptake were detected by FDG
PET (A) and SRS (B). Some lesions showed both radiotracer uptake and other exclusive uptake of FDG or labeled
somatostatin analogs (arrowhead). The discrepancy between the results of pathologic reports and isotopic procedures
strongly suggests different degrees of tumor differentiation in the same patient.
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Figure 6 FDOPA PET (A,D), FDG PET (B,F) and enhanced CT (C,E) results of a 65-year-old patient with a duodenal
NET and liver metastatic involvement. Biopsy of one hepatic localization showed a well-differentiated carcinoma with Ki-
67 index of 10%. The pathologic examination of the primary tumor showed poorly differentiated carcinoma with a Ki-67
index of 10%. Both FDG PET and FDOPA PET showed multiple non-concordant foci of pathologic uptake in the liver
(arrowheads).
Figure 7 FDG PET (A,C) and FDOPA PET (B,E) results for a 68-year-old patient with clinical and biological
suspicion of NET. FDG PET showed an exclusive pathologic uptake in hepatic segment IVVIII, corresponding to a
metastatic lesion on enhanced CT (D). Biopsy of hepatic metastasis (arrowheads) showed a well-differentiated NET of
unknown origin with a Ki-67 index of 3%. FDOPA PET showed the ileal primary tumor (*) and multiple hepatic and
lymph node metastases.
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The management of patients with NET largely depends
on the results of pathologic examination, which allows
differentiation of aggressive malignancies from low-grade
tumors. Generally, grade and differentiation are deter-
mined from a limited tissue sample obtained from
biopsy or from partial surgical resection, which might
be not truly representative of the whole tumor burden.
On the other hand, nuclear medicine provides whole-
body imaging, allowing extensive in vivo characterization
of the tumor that is potentially useful for guiding biopsy,
in particular of FDG-avid lesions that are not clearly
detectable on CT or are largely necrotized or are avid
in only a part (Fig. 7).
The prediction of patient outcome is a real challenge in
clinical routine. Recently, the usefulness of nuclear med-
icine imaging for predicting patient prognosis has been
advocated. Particularly, examinations based on FDG
PET and radiolabeled somatostatin analogs may provide
prognostic information independently from the patho-
logic indexes that are commonly accepted and used in
daily routine. Moreover, tumor FDG uptake seems to be
associated with a worse patient outcome even in well-
differentiated or low-grade tumors. Despite the existence
of a relationship between the tumor scintigraphic pattern,
cellular differentiation, tumor grade and patient outcome,
the intimate mechanism explaining the variability of the
results has not been completely elucidated[59].
In conclusion, we emphasize the emerging role of
nuclear medicine imaging in the management of NET.
Hence, a better understanding of tumor biology and
pathophysiology seems necessary to improve patient out-
come. Prospective studies including larger and homoge-
neous patient series taking into account both cellular
differentiation and tumor grade are necessary to confirm
the real place for nuclear medicine in the diagnosis and
follow-up of patients with NET.
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